Extended Inflammation Parameters (EIP) as Markers of Immune System Cell Activation in Psoriasis

Table 1

Characteristics of the study group and the control group.

		Total N = 61, range (N) (average (%))
	Demographic data
		Study group = 31	Control group = 30
1.	Age (years)	19–71 (43)	21–72 (49)
2.	Male gender	22 (70.9)	12 (40,0)
	Clinical data
3.	Smoking	3 (9.7)	5 (16.7)
4.	Time since psoriasis diagnosis (years)	1.5–39.0 (15.0)	—
5.	Accompanying chronic diseases	18 (58.1)	10 (33.3)
6.	Cancers	0	0
7.	Immunosuppressive treatment	22 (70.9)	0
	Laboratory data
8.	CRP (mg/l)	0.6–17.0 (4.39)	1.0–8.9 (3.06)
9.	ESR (mm/h)	23–98 (36.5)	2–19 (1.23)
10.	WBC (10^3/μl)	4.46–10.59 (7.13)	3.44–9.78 (6.26)
11.	NEUT (10^3/μl)	1.99–8.40 (4.09)	1.56–5.78 (3.54)
12.	NEUT (%)	38.1–79.4 (56.3)	32.5–61.0 (52.1)
13.	LYMPH (10^3/μl)	1.07–3.52 (2.20)	1.15–2.94 (2.01)
14.	LYMPH (%)	14.3–49.5 (31.6)	18.1–41.1 (30.8)
15.	INFγ (pg/ml)	0.64–5.70 (1.95)	0.15–2.51 (1.84)
16.	ANG II (pg/ml)	25.44–125.70 (54.4)	25.98–68.52 (46.15)

Including pulmonary sarcoidosis, nephrolithiasis, inflammation of the duodenal mucosa, bronchial asthma, hypertension, hypercholesterolaemia, urinary tract infection, gout, diabetes, chronic heart failure, obesity, depression, hypothyroidism, degenerative spine disease, arthrosis, and juvenile acne. N: the number of all variables; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; WBC: white blood cells; NEUT: neutrophils; LYMPH: lymphocytes; INFγ: interferon gamma; ANGII: angiotensin II.